SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/20.09.24

SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/20.09.24 Share Price

DE000SW1YSV7

Market Closed - Börse Stuttgart 01:26:44 14/06/2024 pm IST
0.007 ^EUR	+16.67%

Current month	+133.33%
1 month	-12.50%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/20.09.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment	14/06	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	14/06	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	14/06	DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	14/06	BU

More news

Quotes 5-day view

Date	Price	Change
14/24/14	0.007	+16.67%
13/24/13	0.006	0.00%
12/24/12	0.006	+100.00%
11/24/11	0.003	-57.14%
10/24/10	0.007	+133.33%

Delayed Quote Börse Stuttgart

Last update June 14, 2024 at 01:26 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SW1YSV
ISIN	DE000SW1YSV7
Date issued	07/08/2023
Strike	65 $
Maturity	20/09/2024 (97 Days)
Parity	10 : 1
Emission price	0.43 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.48 €
Lowest since issue	0.003 €
Delta	0.04x
Omega	11.12
Premium	58.12x
Gearing	285.08x
Moneyness	0.6338
Difference Strike	23.8 $
Difference Strike %	+36.62%
Spread	0.013 €
Spread %	65.00%
Theoretical value	0.0135
Implied Volatility	46.82 %
Total Loss Probability	97.73 %
Intrinsic value	0.000000
Present value	0.0135
Break even	65.14 €
Theta	-0x
Vega	0x
Rho	0x

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.2 USD

Average target price

53.19 USD

Spread / Average Target

+29.11%

Consensus